CTNM vs SLB · $429.6M cap vs P/E 12, rev $8.97B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US. It is led by Olivier Le Peuch.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
CTNM currently screens at market cap $429.6M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the CTNM and SLB stock pages for the full models.
Not investment advice.